Sarah Wells Kocsis, MBA, coauthor of the Milken Institute report, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management,” discusses how the health care system can better suit the needs of patients with chronic kidney disease (CKD).
Sarah Wells Kocsis, MBA, director of the Center for Public Health at the Milken Institute, talks about the future of chronic kidney disease (CKD) care, which was discussed in a report she coauthored, “Chronic Kidney Disease: Finding a Path to Prevention, Earlier Detection, and Management.”
Transcript
How can our health care system keep changing to better suit the needs of patients with CKD?
What's optimistic and exciting is that I really do believe, based on our work, that we are in a special moment in time right now, both for public health and for CKD. COVID-19 has really put a spotlight around public health and how important it is, and it's really garnered societal attention about its relevance and why it's needed. For CKD, there's been a lot of progress. There's been new therapies, there's been new technology platforms, there's been better data, and there's been machine learning. So when you sort of combine the attention around public health and the need for it, and the need for public health approaches, and you attach that to CKD and building momentum, that really translates into some excellent progress right now. So we really need to build on that momentum.
We also felt that, in uncovering emerging trends in this report and work, we identified some behavioral shifts that are important. And so I think as we move forward, it's not important just to identify the changes in the trends, but to track them, measure them, evaluate them, and modify them. And by doing that, we're going to be able to better deeply understand the impact that this disease has on morbidity, mortality, quality of life. And we need to do that for people who have been diagnosed with CKD, but also all the people out there who are at risk for the disease and don't even know that they have it.
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More